A look at financing, M&A, and alliance activity January–March 2015
• By Maureen Riordan and Amanda Micklus
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.
Representing a 72% increase over Q4 2014, first-quarter 2015 financing totaled $15.1 billion and featured 187 transactions (52 more than Q4). (See Exhibit 1.)
Exhibi
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.
Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.
After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.